Cipla shares rise after Vysov anti-diabetic drug acquisition
Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the company said in a regulatory filing.
By PTI | Updated:
BCCL
New Delhi: Shares of pharma company Cipla on Tuesday gained over 1 per cent after the firm acquired brand name and trademark rights of Vysov for anti-diabetic drug Vildagliptin.
The homegrown pharma major on Monday said it has acquired brand name and trademark rights for Vysov for anti-diabetic drug Vildagliptin for the Indian market from Novartis.
Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the company said in a regulatory filing.
The market size of Vildagliptin in India is Rs 818 crore as per IQVIA MAT data of November 2019, Cipla said.
The shares of the company closed 1.12 per cent higher at Rs 463.75 on BSE.
The homegrown pharma major on Monday said it has acquired brand name and trademark rights for Vysov for anti-diabetic drug Vildagliptin for the Indian market from Novartis.
Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the company said in a regulatory filing.
The market size of Vildagliptin in India is Rs 818 crore as per IQVIA MAT data of November 2019, Cipla said.
The shares of the company closed 1.12 per cent higher at Rs 463.75 on BSE.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
